Area of research
Physiology · Psychiatry and Mental health
Research interest
Research interests include Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Neuroinflammation and Neurodegeneration Mechanisms, and Amyotrophic Lateral Sclerosis Research.
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
A minimally invasive dried blood spot biomarker test for the detection of Alzheimer’s disease pathology
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease.
Distinct alterations of adiponectin, fibroblast growth factor 21 (FGF-21), and insulin-like growth factor binding protein 2 (IGFBP-2) link dysmetabolism with cognitive decline across the Alzheimer's disease spectrum.
Inflammation, Limbic White Matter Microstructure, and Clinical Symptoms in Retired American Football Players With Repetitive Head Impacts
Tracking the turning point in Alzheimer's disease.
Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias.
Ferroptosis in microglial activation: a systematic review and multidata comparison.
Increased cerebrospinal fluid YKL-40 concentration in hip fracture patients with delirium.
A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis.
Intracellular fluid accumulation underlies brain volume increases in early Alzheimer's disease.
Head-to-head comparison of brain-derived pTau217 and total pTau217 for brain amyloid and tau pathology classification.
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data.
Cerebrospinal fluid levels of neurogranin and YKL-40 in mild cognitive impairment due to Alzheimer's disease or vascular dementia.
Vascular stiffness predicts plasma markers of neurodegeneration among older African Americans.
Midlife plasma proteomic profiles indicate altered amyloid and tau processing in former elite rugby players.
Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?
Neuroaxonal Injury in Acute HIV Infection and Following Immediate Antiretroviral Therapy.
Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults.
Effect of 6-week tadalafil treatment on blood-based biomarkers of neurodegeneration: A post-hoc analysis of a randomized controlled trial
Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease.
Early functional changes and plasma GFAP in Swedish families with Autosomal Dominant Alzheimer’s disease mutations
Circulating Sphingomyelins Correlate With Plasma T‐Tau in Cognitively Unimpaired Older Adults at Risk of Developing Alzheimer's Disease
Cortical mean diffusivity detects early age-related changes and associates with cognition and plasma biomarkers.
Biomarker-integrated prognostic stagings for Alzheimer’s Disease
N‐Truncated Superoxide Dismutase‐1 in Cerebrospinal Fluid Is Folded and Active
Subjective estimation of cognitive function in mild cognitive impairment: relationship with neurodegenerative and non-degenerative factors.
Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms: Tau-enriched and Tau-scarce cohorts for cost-effective clinical use
Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease Continuum.
Blood-based AT(N) biomarkers for Alzheimer's disease and frontotemporal lobar degeneration in Latin America.